冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司)(Live-attenuated hepatitis A virus vaccine(Zhejiang Pukang Biologic Technology Co Ltd))

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

Hepatitis A (Live) Vaccine,Freeze-dried、冻干甲型肝炎减毒活疫苗（浙江普康）

靶点-

作用机制

免疫刺激剂

治疗领域

感染消化系统疾病

在研适应症

甲型肝炎

非在研适应症-

原研机构

浙江普康生物技术股份有限公司

在研机构

浙江普康生物技术股份有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2000-01-01),

甲型肝炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

2

项与冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司) 相关的临床试验

ChiCTR2000040323 / Suspended临床4期IIT

A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA-L)

开始日期2020-12-11

申办/合作机构-

CTRI/2012/07/002757 / Not yet recruiting临床3期

An Open label evaluation of Immunogenicity and Safety of Biovac-A Freeze Dried, Live Attenuated Hepatitis-A Vaccine in healthy children

开始日期2012-07-10

申办/合作机构

Wockhardt Ltd.

100 项与冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司) 相关的临床结果

登录后查看更多信息

100 项与冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司) 相关的转化医学

登录后查看更多信息

100 项与冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司) 相关的专利（医药）

登录后查看更多信息

42

项与冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司) 相关的文献（医药）

2024-08-01·Heliyon

Cellular immune response to a single dose of live attenuated hepatitis a virus vaccine in obese children and adolescents

Article

作者: Buranapraditkun, Supranee ; Eiamkulbutr, Sutha ; Tubjareon, Chomchanat ; Prachuapthunyachart, Sittichoke ; Suratannon, Narissara ; Chongsrisawat, Voranush ; Soponkanabhorn, Tanatchabhorn

BackgroundLimited data are currently available regarding the cellular immune response to a live attenuated hepatitis A virus (HAV) vaccine, especially in children with obesity. The objective of this retrospective cohort study was to compare the activation of antigen-specific interferon (IFN)-γ+ T cells in obese children and adolescents with healthy individuals before and after immunization with a single dose of live attenuated HAV vaccine.MethodsBlood samples were obtained from the 2021 study by Dumrisilp et al. investigating the immunogenicity of the live attenuated hepatitis A vaccine in children and young adults. Prior to enrollment, all 212 subjects had never received any HAV vaccine and tested negative for anti-HAV antibodies. The participants were vaccinated with a freeze-dried, live attenuated HAV vaccine of the H2 strain. In this study, we analyzed the stored peripheral blood mononuclear cells (PBMCs) obtained from a subgroup of 30 obese subjects and 30 normal-weight healthy controls of the same age and sex. PBMCs were collected before and 8-9 weeks after HAV vaccination for further analysis. These cells were stimulated with a recombinant antigen derived from HAV-VP3, and the immune response was evaluated using the IFN-γ enzyme-linked immunospot (ELISpot) assay.ResultsThe between-group analysis indicated that the T-cell response of obese participants was comparable to that of normal-weight controls both before and after vaccination. The change in IFN-γ production from before to after vaccination in the obese group was not significantly different from that of the control group. Additionally, in the obese group, no correlation was found between IFN-γ production and clinical characteristics such as sex, body mass index, waist circumference, and acanthosis nigricans.ConclusionTesting for cellular immune response provides a comprehensive understanding of the overall immune response to vaccination. This study, the first to explore this significant aspect, suggests that obesity does not affect the short-term cellular immune response to live attenuated HAV vaccination.

2022-10-26·Journal of Virology

Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups

Article

作者: Bonifacio, João P. P. L. ; Schmolke, Mirco ; Williams, Nathalia ; Garnier, Laure ; Mazel-Sanchez, Beryl ; Hugues, Stephanie

Live attenuated influenza vaccine (LAIV) is a needle-free, mucosal vaccine approved for healthy 2- to 49-year old individuals. Its replicative nature and higher rate of adverse events excludes at-risk populations.

2021-12-01·Journal of Viral Hepatitis2区 · 医学

Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up

2区 · 医学

Article

作者: Zhao, Gan ; Kilgore, Paul E. ; Zhao, Yu‐Liang ; Qiu, Chao ; Zhang, Yan‐Hong ; Wang, Song‐Mei ; Ma, Jing‐Chen ; Zhang, Xin‐Jiang ; Chen, Ying ; Wang, Xuan‐Yi ; Hao, Zhi‐Yong ; Zhang, Zhi‐Yong

In this report, we provide a comprehensive assessment of antibody persistence at 17-yr following receipt of single dose of HA vaccine.

100 项与冻干甲型肝炎减毒活(浙江普康生物技术股份有限公司) 相关的药物交易

登录后查看更多信息